Table S2.

LS mean percentage changes from baseline in RV/TLC at day 2 and week 12

LS mean percentage change from baseline	UMEC/VI 62.5/25 μg vs PBO	UMEC 62.5 μg vs PBO	VI 25 μg vs PBO	UMEC/VI 62.5/25 μg vs UMEC 62.5 μg	UMEC/VI 62.5/25 μg vs VI 25 μg
Day 2
na	281/317	88/317	139/317	281/88	281/139
RV/TLC (trough)	−7.3	−5.8	−4.9	−1.5	−2.5
95% CI	−8.7 to −6.0	−7.8 to −3.8	−6.6 to −3.2	−3.6 to 0.5	−4.2 to −0.7
P-value	<0.001	<0.001	<0.001	0.137	0.006
RV/TLC (3 hours postdose)	−10.0b,c	−8.0c	−7.4c	−2.0b	−2.7b
95% CI	−11.4 to −8.6	−10.1 to −5.9	−9.2 to −5.6	−4.1 to 0.1	−4.5 to −0.9
P-value	<0.001	<0.001	<0.001	0.058	0.004
Week 12
na	248/268	81/268	120/268	248/81	248/120
RV/TLC (trough)	−7.7	−5.3	−4.5	−2.4	−3.1
95% CI	−9.4 to −6.0	−7.8 to −2.8	−6.7 to −2.4	−4.9 to 0.1	−5.3 to −0.9
P-value	<0.001	<0.001	<0.001	0.064	0.005
RV/TLC (3 hours postdose)	−9.8	−7.1	−6.1	−2.7	−3.8
95% CI	−11.6 to −8.0	−9.7 to −4.5	−8.3 to −3.8	−5.4 to −0.1	−6.1 to −1.5
P-value	<0.001	<0.001	<0.001	0.042	0.001

Notes:

^aPatients with analyzable data at the given time point (treatment/comparator);

^bUMEC/VI, n=280;

^cPBO, n=316.

Abbreviations: CI, confidence interval; LS, least squares; PBO, placebo; RV, residual volume; TLC, total lung capacity; UMEC, umeclidinium; VI, vilanterol.